STARCEF Capsule
ក្រុមហ៊ុនផលិតឱសថ:
PT Dexa Media, Indonesia
ក្រុមហ៊ុនចែកចាយឱសថនៅប្រទេសកម្ពុជា:
Dynamic Pharma
and
- សារធាតុសកម្ម
- ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
- ហាមប្រើ
- ផលរំខាន
- អន្តរប្រតិកម្ម
- ការប្រុងប្រយ័ត្នជាពិសេស
- សកម្មភាពឱសថ បរិយាយប័ណ្ណឱសថ
-
សារធាតុសកម្ម
-
ប្រសិទ្ធិភាពព្យាបាល និង កម្រិតប្រើប្រាស់
Urinary infections without complication caused Escherichia coli and Proteus mirabilis
• Otitis media caused by Haemophilus influenzae (β-lactamase positive and negative strains),
Moraxella (Branhamella) catarrhalis (most of which are β-lactamase positive) and Streptococcus pyogenes
• Pharyngitis and tonsillitis caused by Streptococcus pyogenes
• Acute bronchitis and acute exacerbation of chronic bronchitis, caused by Streptococcus pneumoniae and Haemophilus influenzae (β-lactamase positive and negative strains)
For adults and children weighing > 30 kg,the usual daily dose is 50-100 mg of cefixime given orally twice a day. Dosage should be adjusted according to age,body weight,and condition of the patients. For severe infections,the dosage may be increased up to 200 mg,given twice a day.
-
ហាមប្រើ
Patients with history of shock or hypersensitivity due to any ingredients of STARCEF
-
ផលរំខាន
Shock
Adequate caution should be exercised since shock symptoms may sometimes occur. If any related signs or symptoms,e.g. dysphoria,oral cavity discomfort,stridor,dizziness,abnormal urge to defecate,tinnitus or diaphoresis occur,STARCEF must be discontinued immediately.
Hypersensitivity
If signs of hypersensitivity reactions, e.g. rash,urticaria,erythema,pruritus or fever occur,the administration of STARCEF should be discontinued and appropriate measures should be taken.
Hematology
Granulocytopenia or eosinophilia may occur rarely. Sometimes, thrombocytopenia may also occur. The use of STARCEF should be discontinued if any of such disorders is found. It has been reported that hemolytic anemia has occurred in the use of other cephems
Hepatic
Infrequently, an increase in GOT,GPT or alkaline phosphatase may occur
Renal
Periodic monitoring of renal function is recommended since serious renal impairment,e.g. renal insufficiency may sometimes occur. If any of such abnormalities is found,STARCEF should be discontinued and appropriate measures should be taken
Digestive
In rare instances,a serious colitis,e.g. pseudomembranous colitis,manifested by blood in stools may occur
Respiratory
In rare instances,interstitial pneumonia or PIE syndrome,manifested by fever,cough,dyspnea,abnormal chest X-ray or eosinophilia may occur. If any such symptoms occur,STARCEF should be immediately discontinued and appropriate measures,e.g. administration of adrenocortical homones should be taken
Alteration in bacterial flora
Stomatitis or candidiasis may occur rarely
Vitamin deficiencies
Vitamin K deficiencies,e.g. hypoprothrombinemia or bleeding tendencies or vitamin B complex deficiencies (e.g. glossitis,stomatitis,anorexia or neuritis) may occur infrequently.
Others
Headache or dizziness may occur rarely. In studies where infant rats were given 1000 mg/kg body weight/day orally, a reduction in spermatogenesis was reported
-
អន្តរប្រតិកម្ម
Carbamazepine
Elevated carbamazepine levels have been reported in postmarketing experience when cefixime is administered concomitantly. Drug monitoring may be assistance in detecting alterations in carbamazepine plasma concentrations
-
ការប្រុងប្រយ័ត្នជាពិសេស
General
Caution should be exercised since hypersensitivity reactions, e.g. shock may occur. STARCEF should not be administered in patients who may still be treated with other antibiotics. If necessary, it should be administered with caution. Patients with history or hypersensitivity to any ingredient of STARCEF or any other cephem antibiotics. Cefixime should be administered carefully to the following patients:
- Patients with a history of hypersensitivity to penicillin.
- Patients with a personal or familial history to various forms of allergy, e.g. bronchial asthma, rash and urticaria.
- Patients with serious renal dysfunction.
- Patients with poor oral nutrition, those receiving parenteral nutrition, the elderly or patients in debilitated state. These patients must be monitored as vitamin K deficiency symptoms may develop.
-
សកម្មភាពឱសថ
inhibition of cell wall synthesis
*ព័ត៌មានឱសថត្រូវបានរៀបរៀងដោយ អ៊ីម៉ាតុគឹ មេឌីក (ខេមបូឌា) ដោយផ្អែកលើប្រភពព័ត៌មានខាងក្រោម។ សម្រាប់ព័ត៌មានលម្អិត សូមស្វែងរកនៅក្នុងក្រដាសព័ត៌មាននៃឱសថនីមួយៗ ឬ សាកសួរទៅកាន់ក្រុមហ៊ុនឱសថឬតំណាងចែកចាយនៃឱសថនីមួយៗ។
ប្រភពព័ត៌មាន៖
- ក្រដាសព័ត៌មាននៃឱសថសម្រាប់អ្នកជំនាញវេជ្ជសាស្ត្រដែលប្រើប្រាស់នៅប្រទេសជប៉ុន (Pharmaceutical and Medical Devices Agency, Pmda): https://www.pmda.go.jp
- ព័ត៌មានសង្ខេបនៃឱសថសម្រាប់អ្នកជំងឺដែលប្រើប្រាស់នៅប្រទេសជប៉ុន: http://www.rad-ar.or.jp